Daniel J. Lenihan et al. BTS 2016;1:

Slides:

Advertisements

Similar presentations

Charlotte Kragelund et al N Engl J Med 2005;352: Baseline Clinical Characteristics According to Quartiles of NT-pro-BNP.

Advertisements

COPERNICUS: Carvedilol Prospective Randomized Cumulative Survival trial Purpose To assess the effect of carvedilol, a β 1 -, β 2 - and α 1 -receptor blocker,

Dronedarone in patients with congestive heart failure: insights from ATHENA by Stefan H. Hohnloser, Harry J.G.M. Crijns, Martin van Eickels, Christophe.

Copyright © 2009 American Medical Association. All rights reserved.

Tissue Velocities and Myocardial Deformation in Asymptomatic and Symptomatic Aortic Stenosis Helle Gervig Carstensen, MD, PhD, Linnea Hornbech Larsen,

Daniel J. Lenihan et al. BTS 2016;1:

Number of Indicators Improved or Worsened, by State

Name: _______________________________

Rank-order bar chart of percentage of patient-days with blood glucose results > 299 mg/dl for non-ICU units. Rank-order bar chart of percentage of patient-days.

Shadi Al Halabi et al. JACEP 2015;1:

Carolyn Y. Ho et al. JCHF 2015;3:

Patients with Kawasaki disease but not those with mimicking conditions have significantly elevated serum and urine levels of meprin A and filamin C, which.

Mirnela Byku, and Douglas L. Mann BTS 2016;1:95-106

Serum levels of IL-21 are elevated in a subset of patients with IM

Fig. 1. Serum HBsAg, HBcrAg, and HBeAg reduction in human patients treated with a single dose of ARC-520. Serum HBsAg, HBcrAg, and HBeAg reduction in human.

Daniel J. Lenihan et al. BTS 2016;1:

Database-specific risk of ventricular arrhythmia associated with current use of azithromycin compared with current use of amoxicillin (2-stage random-effects.

Heiko Lehrmann et al. JACEP 2018;j.jacep

The effect of GOODCOLL versus POORCOLL on LVEF, LVEDV and scar at 4 months. The effect of GOODCOLL versus POORCOLL on LVEF, LVEDV and scar at 4 months.

Daniel J. Lenihan et al. BTS 2016;1:

Voluntary but not forced exercise alters food consumption in mice.

Mohit K. Turagam et al. JACEP 2017;3:

Prabhat Kumar et al. JACEP 2016;j.jacep

Isaac Perea-Gil et al. BTS 2016;1:

Heather M. Wilson et al. BTS 2018;3:

Relationship between the premature ventricular contraction (PVC) prevalence and change in left ventricular diastolic dimension (ΔLVDd) during the 4-year.

Bar chart of cardiac volumes and EF in the healthy individuals, HCM LVH− patients and HCM LVH+ patients. Blue bars show the indexed diastolic volumes (EDVI.

Volume 114, Issue 6, Pages (June 1998)

Baseline Left Ventricular Volume and Shape as Determinants of Reverse Remodeling Induced by Surgical Ventricular Reconstruction Marisa Di Donato, MD,

Romain Gallet et al. BTS 2016;1:14-28

More improvement than decline

Masanobu Ishii et al. BTS 2017;2:

Romain Gallet et al. BTS 2016;1:14-28

Minimal dose for effective clinical outcome and predictive factors for responsiveness to carvedilol: Japanese chronic heart failure (J-CHF) study Hiroshi.

LV Structure, Function, and Circulating BNP Levels at 18 Weeks Post TAC (A) (B) LVEDD and LVESD (mm) throughout the experimental protocol. (C) Percent.

Christopher T. Nguyen et al. BTS 2018;3:97-109

Receiver operating characteristic curves for the association of primary outcome using each clinical risk score and each clinical risk score adjusted for.

Time course of changes in left ventricular ejection fraction (LVEF) and left ventricular diastolic dimension (LVDd) in 13 patients with the development.

Cumulative survival without events during 1 year in patients with preserved systolic function (left ventricular ejection fraction (LVEF) >40%) and with.

Associations between β-blocker dosage group, predischarge heart rate group, and the primary composite outcome of death or cardiovascular rehospitalisation.

Relationship between the change in left ventricular ejection fraction (ΔLVEF) and change in left ventricular diastolic dimension (ΔLVDd) at 4 years at.

Jordan S. Leyton-Mange et al. JACEP 2017;j.jacep

mpJX-594 effects on tumor burden and leukocyte influx.

J. Craig Hartman et al. BTS 2018;3:

Patient selection. *This category included 10 patients with suspected tachyarrhythmia, 9 treated for cancer with cardiotoxic cytostatics and/or transthoracic.

Flow chart patient inclusion.

Evolution of Myocardial Blush after MI

Associations between presence of tachycardia at time of admission (heart rate ≥120/min) and the primary composite outcome of death or cardiovascular rehospitalisation,

Altered mycobiota and bacterial-fungal correlation in AS patients receiving different therapeutic regimens. Altered mycobiota and bacterial-fungal correlation.

Fig. 4 Pupil shape and image quality in the model sheep eye.

Regorafenib inhibits angiogenesis and induces apoptosis.

Relationship between FFM, daily EI and daily profile of hunger.

Assessment of infarct size by biomarker measurement.

Sagittal view of hypothalamus showing a significant reduction in CBF 15 and 30 min after application of intranasal insulin compared with placebo in the.

Absolute mortality difference Change in LVEF from baseline

Average left ventricular ejection fraction (LVEF) values during the 1 year of observation in patients with preserved systolic function (LVEF >40%) and.

Satoru Kishi et al. JCHF 2014;2:

Effects of MPH on 19 single neuron response metrics.

Histograms of LVESVI, LVEDVI, LVMI, and 3D LVEF Tabulations of frequencies of left ventricular end-systolic volume (A), end-diastolic volume (B), mass.

Scatter plot of relationship between MWT, GLS and EF upper panel shows that GLS was closely related to MWT with worse LV function by GLS correlating to.

John P. Boehmer et al. JCHF 2017;5:

Evan M. Zahn et al. JCIN 2016;9: Relationship Between Patent Ductus Arteriosus Closure and Left Ventricular Ejection Fraction The graph depicts.

Left ventricular ejection fraction in patients without CAD (no CAD), with established CAD without MI (CAD, no MI), and patients with CAD and previous MI.

Time to first event analysis revealed a significant difference in estimated event-free (death or hospitalisation) survival between patients with left ventricular.

Immune signatures of patients with short-, medium-, and long-term survival. Immune signatures of patients with short-, medium-, and long-term survival.

Patient selection process in the present study.

Changes in clinical parameters and use of catecholamines during hospitalisation (A) inotropic score, B) serum lactate levels and (C) SAPS II from baseline.

ROC analysis of MIC-1 and CA19-9.

Heritability estimates in percentages using structural equations modelling for primary trait phenotypes in DCM (LVEF and LVEDD), HCM (IVSd) and LQTS (QTc).

Fig. 3 Gene expression analysis in 48-plex drug treatment experiments.

Presentation transcript:

Daniel J. Lenihan et al. BTS 2016;1:576-586 Mean AUC for Absolute Change in LVEF Over 90 Days (A) The mean AUC for change in LVEF over 90 days in all patients is displayed for the placebo (grey), low-dose (green), and high-dose (blue) groups (with the lighter portion in the high-dose group including cohort 7). The high-dose group had a significantly greater increase in LVEF when compared with the low-dose or placebo groups. This was significant whether the highest dose (1.5 mg/kg) cohort was included (lighter blue bar) or not (darker blue bar) (p < 0.01). (B) The mean AUC for change in LVEF over 90 days in all patients is displayed for each individual dose cohorts and plotted on a logarithmic scale. The individual dose cohorts that were grouped into the placebo, low and high dose are color coded as in A. R2 = 0.6735. The Jonckheere-Terpstra test showed a significant relationship between dose and change in LVEF AUC 0-90 (p = 0.0012). AUC = area under the curve; LVEF = left ventricular ejection fraction. Daniel J. Lenihan et al. BTS 2016;1:576-586 The Authors